CLINICAL TRIAL ALERT
As you can imagine, COVID-19 is affecting every aspect of life, including clinical trial research studies. AAKP wants to provide some guidance to kidney patients interested in participating in clinical studies and those already participating in clinical studies:
- If you interested in a clinical trial, please consider waiting until the COVID-19 situation has either declined or reaches manageable levels for high, at-risk populations. Currently, study centers are under extreme pressure to make modifications to continue their trials in the safest way possible and may not be enrolling new trial participants or may not responded to inquires immediately.
- If you are already in a clinical study, thank you for doing this! Your contributions are very important to the long-term advancements in patient care. Please continue to take your study drug as prescribed. Also, stay in close contact with your study center for study specific instructions and to confirm what their plans are for you. Some study centers may be able to continue to see you and resupply your study drug. Other sites may not be able to see you, but may be able to ship your study drug to you.
AAKP’s role in Clinical Trials and Market Research
AAKP supports innovation in the kidney space. We are actively involved in market research – to share the patient voice and experience with renal companies and clinical trials – to create more and better treatment options for kidney patients, so they can achieve their aspirations.
You may have heard the term “clinical trials” but wonder what that means. Is a clinical trial something you can participate in? What do you need to do to get started? We have pulled together some information that you might find helpful as you decide whether you would like to participate in a clinical trial.
Clinical Trials and Market Research Opportunities
Below is a list of the Clinical Trials and Market Research opportunities that AAKP is partnering to raise awareness of. You can also use the search tool below to be matched to even more opportunities.
| Name | Description | Learn More |
|---|---|---|
| PROTECT Study | Retrophin is now enrolling patients in the PROTECT Study, a global Phase 3 clinical study investigating the safety of sparsentan and the effects it has on the amount of protein in the urine (proteinuria) and on kidney function in patients with IgAN. | Click here to read more about this opportunity. |
| DUPLEX Study | Retrophin is now enrolling patients in the DUPLEX Study, a global Phase 3 clinical study investigating the safety of sparsentan and the effects it has on the amount of protein in the urine (proteinuria) and on kidney function in patients with FSGS. | Click here to read more about this opportunity. |
| ARENA 2 Study for primary dRTA | This clinical study is enrolling patients between 6 months and 65 years of age who have been diagnosed with distal renal tubular acidosis. The ARENA-2 trial is studying how well the medication ADV7103, taken twice a day, treats dRTA. | Click here to read more about this opportunity. |
| FALCON Study | FALCON is a Phase 3 clinical study evaluating the effectiveness and safety of bardoxolone methyl (an oral investigational drug) in patients with ADPKD. The investigational drug, study-related procedures, and doctor visits will be provided at no cost. Visit PKDstudy.com for more information. | Click here to read more about this opportunity. |
| Emerald Study | Ongoing Pediatric Clinical Trial. Parents – do you have a child between the ages of 2 and 12 with kidney disease who also struggles to manage high blood potassium levels? | Click here to read more about this opportunity. |
| Bristol-Myers Squibb Study | Do you struggle to manage FSGS or Minimal Change Disease? If so, you might be eligible to enroll in a new clinical trial. Visit www.KidneyClinicalTrial.com. | Click here to read more about this opportunity. |
